Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1100/tsw.2002.863 http://scihub22266oqcxt.onion/10.1100/tsw.2002.863 C6009530!6009530!12806171     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       ScientificWorldJournal 2002 ; 2 (ä): 1808-15 Nephropedia Template TP {{tp|p=12806171|t=2002. High Dose Cyclophosphamide Treatment for Autoimmune Disorders |pdf=|usr=}}{{12806171}} gab.com Text High Dose Cyclophosphamide Treatment for Autoimmune Disorders JO: ScientificWorldJournal http://www.kidney.de/pget.php?&tw=1&pmid=12806171 #FOAvip High-dose cyclophosphamide (200 mg/kg) was initially developed as a conditioning regimen for allogeneic bone marrow transplantation. Recently, high-dose cyclophosphamide without bone marrow transplantation has been employed as a method to induce durable treatment-free remissions in severe aplastic anemia and a variety of other severe autoimmune disorders. The premise underlying this approach is that high-dose cyclophosphamide is maximally immunosuppressive, but not myeloablative. Early hematopoietic stem cells are spared the cytotoxicity of cyclophosphamide because of their high levels of aldehyde dehydrogenase, an enzyme that confers resistance to the drug. Conversely, autoimmune effector cells (T cells, B cells, and NK cells) are exquisitely sensitive to high-dose cyclophosphamide because of their relatively low levels of aldehyde dehydrogenase. Intensive investigation is underway to determine which autoimmune disorders will most benefit and where in the natural history of these diseases to employ this rapidly developing therapy. Twit Text FOAVip High Dose Cyclophosphamide Treatment for Autoimmune Disorders ????ScientificWorldJournal http://www.kidney.de/pget.php?&tw=1&pmid=12806171 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=12806171 #FOAvip English Wikipedia <ref>{{Cite pmid|12806171}}</ref> High Dose Cyclophosphamide Treatment for Autoimmune Disorders #MMPMID12806171 Brodsky RA ScientificWorldJournal 2002[]; 2 (ä): 1808-15 PMID12806171show ga High-dose cyclophosphamide (200 mg/kg) was initially developed as a conditioning regimen for allogeneic bone marrow transplantation. Recently, high-dose cyclophosphamide without bone marrow transplantation has been employed as a method to induce durable treatment-free remissions in severe aplastic anemia and a variety of other severe autoimmune disorders. The premise underlying this approach is that high-dose cyclophosphamide is maximally immunosuppressive, but not myeloablative. Early hematopoietic stem cells are spared the cytotoxicity of cyclophosphamide because of their high levels of aldehyde dehydrogenase, an enzyme that confers resistance to the drug. Conversely, autoimmune effector cells (T cells, B cells, and NK cells) are exquisitely sensitive to high-dose cyclophosphamide because of their relatively low levels of aldehyde dehydrogenase. Intensive investigation is underway to determine which autoimmune disorders will most benefit and where in the natural history of these diseases to employ this rapidly developing therapy. äHigh Dose Cyclophosphamide Treatment for Autoimmune Disorders (epmc).pdf DeepDyve Pubget Overpricing